A compound of the formula (I):
1
wherein R
1
is hydrogen or lower alkyl;
R
2
is lower alkyl, etc.;
R
3
is lower alkoxy, etc.;
R
4
is hydroxy, etc.;
X is O, S, etc.;
Y is CH or N;
Z is lower alkylene or lower alkenylene; and
m is 0 or 1; or salts thereof, which are useful as a medicament.
Disclosed are methods of identifying, generating and synthesizing compounds that inhibit MAPK13 activity. In various embodiments, compounds, salts thereof and prodrugs thereof of the present teachings can be useful for the treatment of diseases and disorders that involve excess mucus production.
作者:Julie A. Pollock、Naina Sharma、Sirish K. Ippagunta、Vanessa Redecke、Hans Häcker、John A. Katzenellenbogen
DOI:10.1002/cmdc.201800417
日期:2018.10.22
identified a class of triarylpyrazole compounds that inhibit TLR signaling by modulation of the protein–protein interactions essential to the pathway. We have now systematically examined the structural features essential for inhibition of this pathway, revealing characteristics of compounds that inhibited all TLRs tested (pan‐TLR signalinginhibitors) as well as compounds that selectively inhibited certain
申请人:MFC Co.,Ltd. 엠에프씨 주식회사(120080171659) Corp. No ▼ 131411-0209249BRN ▼134-86-46389
公开号:KR20190110400A
公开(公告)日:2019-09-30
본 발명은 신규한 바제독시펜 또는 이의 약제학적으로 허용가능한 염의 제조하는 방법에 관한 것이다. 본 발명에 따른 제조방법은 고순도 및 고수율의 바제독시펜을 제공할 수 있으며, 비교적 간단한 제조 공정으로 시간적, 비용적으로 경제적이고 친환경적이므로, 대량 생산에 유용하게 적용될 수 있다.
A compound of the formula (I):
wherein
R
1
is hydrogen or lower alkyl;
R
2
is lower alkyl, etc.;
R
3
is lower alkoxy, etc.;
R
4
is hydroxy, etc.; X is O, S, etc.; Y is CH or N; Z is lower alkylene or lower alkenylene; and m is 0 or 1; or salts thereof, which are useful as a medicament.